cardiooncology: the promise and pitfalls of personalized ... · cardiooncology:the promise and...
TRANSCRIPT
![Page 1: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/1.jpg)
CardioOncology: The Promise and Pitfalls of Personalized Medicine
Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians
Director, Franciscan Health Inpatient Heart Failure, Cardiac Research and CardioOncology Clinic
![Page 2: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/2.jpg)
Presenter Disclosure Information CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA
I am on the speaker’s bureau for BMS/Pfizer,Boehringer-Ingleheim/Lilly, Novartis
I will not discuss off label or investigational use in my presentation.
![Page 3: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/3.jpg)
Goals & Objectives
Recognize the growing burden of cardiotoxicity from new chemotherapeutic agents
Analyze screening algorithms and risk scores for cardiotoxicity
Recognize potential cardiovascular complications of novel molecular targeted therapies, including arrhythmias, cardiomyopathy, cardiac ischemia and hypertension
![Page 4: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/4.jpg)
Outline
CardioOncology: Historical perspective Radiation therapy and CV disease Anti-Metabolite Coronary Vasospasm Molecular Targeted Therapies (Precision
Medicine) ◦ Trastuzumab (Herceptin®) ◦ Tyrosine Kinase Inhibitors (TKIs) ◦ Checkpoint Inhibitors
![Page 5: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/5.jpg)
2015 CDC US Mortality Data
0 100,000 200,000 300,000 400,000 500,000 600,000 700,000
Suicide
Kidney Disease
Influenza and Pneumonia
Diabetes
Alzheimer's Disease
Stroke
Accidents
Chronic Lower Respiratory Diseases
Cancer
Heart Disease
# of Deaths
Cau
ses
of D
eath
# of Deaths
![Page 6: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/6.jpg)
![Page 7: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/7.jpg)
![Page 8: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/8.jpg)
“One of the goals of cardio-oncology is to prevent the cancer survivor of today from becoming the heart failure patient of tomorrow.”
![Page 9: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/9.jpg)
![Page 10: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/10.jpg)
![Page 11: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/11.jpg)
![Page 12: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/12.jpg)
Anthracyclines In the 1950s, daunorubicin, a compound isolated from
the soil bacterium Streptomyces peucetius, was found effective against tumors in mice, and eventually, acute leukemia and lymphoma.
Among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents
MOA: intercalates between DNA/RNA, affects topoisomerase II, free radial generation - Associated with troubling side-effect: cardiotoxicity
(often irreversible)
![Page 13: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/13.jpg)
Shan et al. Ann Intern Med. 1996;125(1):47-58.
Anthracycline Dose Cardiac Toxicity
![Page 14: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/14.jpg)
Berry GJ, Jorden M. Pediatr Blood & Vancer 2005:44:630-7
![Page 15: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/15.jpg)
Ewer MS and Ewer SM. Nat. Rev. Cardiol. 2010; 7,564–75
![Page 16: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/16.jpg)
![Page 17: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/17.jpg)
Radiation Therapy
Mantle Cell, Adjuvant therapy in breast cancer, Hodgkin’s lymphoma, lung cancer
Cardiac complications when dose is greater than 30 Gy
Shrinking problem: breath holding technique, shielding, smaller fractions, PET scans
![Page 18: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/18.jpg)
Radiation Induced Cardiotoxicity
![Page 19: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/19.jpg)
ASCI-ASE – ESC Expert Consensus 2014
![Page 20: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/20.jpg)
Anti-Metabolite (5-FU): Coronary Vasospasm 5-FU (Fluorouracil®), Capecitabine (Xeloda®),
Gemcitabine (Gemzar®): prevent DNA replication by inhibiting thymidylate synthetase
Used to treat breast, colorectal, pancreatic, skin cancers Up to 2-5% of patients develop chest pain and ST
elevation with coronary vasospasm (usually within 72 h of continuous infusion) and can be lethal
Occurs less often with bolus dosing Occurs more often if patient with pre-existing CV
disease Can consider re-challenge with nitrate/ccb Reversal agent (Vista-guard®) is available but very
expensive
![Page 21: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/21.jpg)
![Page 22: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/22.jpg)
![Page 23: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/23.jpg)
![Page 24: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/24.jpg)
![Page 25: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/25.jpg)
![Page 26: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/26.jpg)
![Page 27: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/27.jpg)
![Page 28: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/28.jpg)
![Page 29: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/29.jpg)
Murphy CG and Morris PG. Anti-Cancer Drugs 2012, 23:765–76
![Page 30: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/30.jpg)
![Page 31: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/31.jpg)
Ewer MS et al. J Clin Oncol 2005;23:7820-6
![Page 32: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/32.jpg)
Echocardiography
![Page 33: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/33.jpg)
Myocardial strain analysis
10% drop in GLS predicts future drop in EF for both anthracycline and trastuzumab chemotherapy
![Page 34: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/34.jpg)
Cardiac MRI
![Page 35: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/35.jpg)
Pharmacologic Treatment for Anthracycline and Trastuzumab Cardiotoxicity
Ace-Inhibitors Beta-blockers (carvedilol, nebivolol) Statins Dexrazoxane
![Page 36: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/36.jpg)
Jensen BV et al. Ann Oncol 2002 13:699-709
![Page 37: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/37.jpg)
Cardinale D et al. JACC 2010,55:213-20
![Page 38: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/38.jpg)
Cardinale D et al. JACC 2010,55:213-20
![Page 39: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/39.jpg)
![Page 40: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/40.jpg)
![Page 41: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/41.jpg)
![Page 42: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/42.jpg)
Angiogenesis Inhibitors: HTN
Drugs: Sorafenib (VEGFR, PDGFR and Raf family kinases), Bevacizumab (VEGFR), Sunitinib (VEGFR, PDGFR)
Prevalence: 15-60% develop HTN Mechanism: Thought due to increased peripheral vascular
resistance due to decreased endothelial nitric oxide synthetase (eNOS) (no relationship seen with humoral factors or volume expansion) Ann Oncol (2007) 18 (6): 1121-1122.
Treatment: Ace-Inhibitors and/or dihydropyridine calcium channel blockers; avoid inhibitors of CYP3A4 (diltiazem, verapamil) as TKIs are substrates, could consider nevibolol (Bystolic) (only beta-blocker which increases NO bioavailability)
May need to decrease dose or halt therapy until HTN controlled; HTN resolves once agent stopped
![Page 43: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/43.jpg)
![Page 44: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/44.jpg)
![Page 45: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/45.jpg)
![Page 46: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/46.jpg)
Checkpoint Inhibitors [Ipilimumab (Yervoy)/Nivolumab (Opdivo)] 1:400 patients estimated to develop myocarditis Moslehi et al. N Engl J Med. 2017 Jan 19;376(3):292
![Page 47: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/47.jpg)
CardioOncology Clinic
Increase awareness about topic and clinical considerations among PCPs and cardiologists
Increase access to subspecialty expertise (telemedicine initiative)
Contribute to research in the field ◦ Incorporating standard CV risk prediction
tools in cardio-onc setting ◦ TKI-HTN grant ◦ SURVIVE registry (10 sites globally)
![Page 48: CardioOncology: The Promise and Pitfalls of Personalized ... · CardioOncology:The Promise and Pitfalls of Personalized Medicine Vijay Rao, MD, PhD, FACC, FASE, FHFSA I am on the](https://reader034.vdocuments.mx/reader034/viewer/2022042121/5e9af53cbce9d6457413be92/html5/thumbnails/48.jpg)
References Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi, M.D.
N Engl J Med 2016; 375:1457-1467 October 13, 2016 DOI: 10.1056/NEJMra1100265
SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory Iliescu et al.
Catheterization and Cardiovascular Interventions 00:00–00 (2015)
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Plana, J.C et al.
J Am Soc Echocardiogr. 2014; 27: 911–939